Test results and clinical details of anti-DFS70–positive patients.
| Sample | ANA-2 IIF Pattern Operator Interpretation LIU (Cutoff = 48) | ANA ELISA/ANA (Cutoff = 1.0) | Anti-DFS70 CIA/CU (Cutoff = 20) | Clinical Details |
|---|---|---|---|---|
| 1 | Centromere/homogenous (232) | Positive (5.21) | 33 | Non-SARD. Lung cancer, pulmonary sarcoidosis. History of anticentromere antibodies. |
| 2 | Speckled (438) | Positive (2.75) | > 450 | Non-SARD. Recurrent blistering. Previous ANA-positive (homogenous) and anti-Scl-70. |
| 3 | Homogenous (179) | Positive (2.54) | 76 | Non-SARD. Ulcerative colitis. No ANA test history. |
| 4 | Centromere (305) | Positive (2.91) | 262 | Non-SARD. Sudden loss of sensation, facial nerve distribution. No ANA test history. |
| 5 | Unrecognised/negative (24) | Positive (1.06) | 119 | Non-SARD. Primary Raynaud, Previous ANA-positive (homogenous). |
| 6 | Homogenous (215) | Positive (3.5) | 52 | Non-SARD. Epilepsy, 2× miscarriages. Positive anticardiolipin, positive lupus anticoagulant. Previous ANA-positive (speckled), ENA-negative. |
| 7 | DFS (146) | Positive (1.01) | 414 | Non-SARD. No ANA test history. |
| 8 | Homogenous (107) | Positive (1.98) | 137 | SARD. SLE monitoring. Previous ANA-positive (homogenous). |
DFS: dense fine speckled; ANA: antinuclear antibodies; LIU: light intensity units; CIA: chemiluminescence immunoassay; CU: chemiluminescent units; SARD: systemic autoimmune rheumatic diseases; ENA: extractable nuclear antigen; SLE: systemic lupus erythematosus.